Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) have revolutionized the treatment landscape for Non-Small Cell Lung Cancer (NSCLC). However, resistance invariably curtails their long-term efficacy. This comprehensive review delineates the intricate mechanisms underpinning EGFR TKI resistance and the evolving therapeutic counterstrategies. We present a panoramic atlas of resistance mechanisms, encompassing on-target resistance, bypass pathway activation, histologic transformation, and metabolic reprogramming, alongside their clinical classification. The discussion extends to the integrated diagnostic technologies facilitating resistance detection, including multi-dimensional biopsy approaches and multi-omics fusion analysis. We critically evaluate precision therapeutic approaches tailored to specific resistance alterations, such as C797S mutations and mesenchymal-epithelial transition amplification, and explore the burgeoning field of novel agents like fourth-generation TKIs and antibody-drug conjugates (ADCs). Furthermore, innovative combination strategies and the challenges within resistance management systems, including toxicity profiles and unresolved scientific questions, are examined. A profound understanding of EGFR resistance mechanisms and the continuous refinement of therapeutic paradigms are paramount for improving the prognosis of NSCLC patients.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: